Elevance Health Inc (ELV · NYSE)

ELV · MARKET VIEW

Market view · as of Aug 24, 2026

Revenue (TTM)
$201.11B
+1.4% YoY
Gross margin
26.0%
EPS (latest q)
$7.45
vs $6.18 est · beat

Elevance Health (ELV) reported Q2 2026 earnings of $7.45 per share, surpassing estimates and prompting management to raise full-year guidance to at least $27 per share. The company posted $50.47 billion in quarterly revenue, while year-over-year earnings declined 13.1% against $31.04 billion in total debt. Currently valued at a market capitalization of $86.86 billion, the stock trades at a 17.73 P/E ratio with a consensus analyst target of $449.10.

Valuation

Market cap
$86.86B
P/E
17.73
PEG
1.418
P/B
1.935
P/S
0.432
Beta
0.692
Analyst target
$449.1

Quality & returns

Gross margin
26.0%
Operating margin
4.6%
Profit margin
2.5%
ROE
11.1%
ROA
3.8%

Quarterly trajectory

Revenue by quarter (oldest → newest)

QuarterRevenueOp incomeNet incomeEBITDA
2026-06-30$50.47B$2.06B$1.46B$2.10B
2026-03-31$50.18B$2.66B$1.76B$2.77B
2025-12-31$49.75B$581.0M$547.0M$987.0M
2025-09-30$50.71B$1.76B$1.19B$2.14B

Recent news

Sources this view read

  • fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
  • filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
  • earnings Reported earnings history (Alpha Vantage EARNINGS)

Other snapshots